Nanoparticle-Based Inhalation Therapy for Pulmonary Diseases

Curr Drug Metab. 2022;23(11):882-896. doi: 10.2174/1389200223666220803103039.

Abstract

The lung is exposed to various pollutants and is the primary site for the onset of various diseases, including infections, allergies, and cancers. One possible treatment approach for such pulmonary diseases involves direct administration of therapeutics to the lung so as to maintain the topical concentration of the drug. Particles with nanoscale diameters tend to reach the pulmonary region. Nanoparticles (NPs) have garnered significant interest for applications in biomedical and pharmaceutical industries because of their unique physicochemical properties and biological activities. In this article, we describe the biological and pharmacological activities of NPs as well as summarize their potential in the formulation of drugs employed to treat pulmonary diseases. Recent advances in the use of NPs in inhalation chemotherapy for the treatment of lung diseases have also been highlighted.

Keywords: Natural polymer; biomedical applications; lung therapy; nanoparticle; phagocytosis; respiratory disease.

MeSH terms

  • Administration, Inhalation
  • Drug Delivery Systems
  • Humans
  • Lung
  • Lung Diseases* / drug therapy
  • Nanoparticles* / chemistry
  • Pharmaceutical Preparations
  • Respiratory Therapy

Substances

  • Pharmaceutical Preparations